Trials / Completed
CompletedNCT03078231
Pilot Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 52 (actual)
- Sponsor
- Eyenuk, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
More than 29 million people in the US are living with diabetes, many of whom will develop diabetic retinopathy (DR) or diabetic eye disease (DED), the leading cause of vision loss and blindness in working-age adults. Annual eye screening is recommended for all diabetic patients since vision loss can be prevented with laser photocoagulation and anti-VEGF injections if DR is diagnosed in its early stages. Currently, the number of clinical personnel trained for DR screening is orders of magnitude smaller than that needed to screen the large, growing diabetic population. Therefore, to meet this large unmet need for DR screening, a fully-automated computerized DR screening system is necessary. This study is designed to assess the performance of EyeArt, an automated DR screening tool.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Color fundus photography | Subjects will undergo fundus photography before and after administration of mydriatic agent. |
| DRUG | Mydriatic Agent | Subjects will be administered mydriatic medication to dilate their pupils. |
Timeline
- Start date
- 2017-02-17
- Primary completion
- 2017-04-24
- Completion
- 2017-04-24
- First posted
- 2017-03-13
- Last updated
- 2018-07-30
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03078231. Inclusion in this directory is not an endorsement.